Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.38 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101324 | 0.71 | KDM4E (0.43) | MAP3K5OGAALDH1A1MAPT | |
| SCHEMBL7920737 | 0.70 | MAP3K5 (0.37) | MAP3K5HDAC4HDAC6 | |
| SCHEMBL8232807 | 0.69 | ERN1 (0.41) | ERN1MAP3K5MAPT | |
| SCHEMBL4999489 | 0.68 | HDAC4 (0.35) | HDAC4HDAC6 | |
| SCHEMBL986122 | 0.68 | STIM1 (0.43) | ERN1MAP3K5ALDH1A1 | |
| SCHEMBL1781405 | 0.67 | IL2 (0.44) | ERN1MAP3K5ALDH1A1MAPT | |
| SCHEMBL16472062 | 0.66 | HTR1F (0.41) | CYP2C19ALDH1A1MAPT | |
| SCHEMBL7924272 | 0.66 | HDAC4 (0.40) | HDAC4HDAC6 | |
| SCHEMBL9383271 | 0.64 | ERN1 (0.49) | ERN1MAP3K5SLC6A15 | |
| SCHEMBL26091050 | 0.64 | ERN1 (0.44) | ERN1MAP3K5SLC6A15ALDH1A1UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | ERN1 3909/4885MAP3K5 1602/4885SLC6A15 4727/4885 |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | ERN1 3909/4885MAP3K5 1602/4885SLC6A15 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.